CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 15.16 HKD -1.04% Market Closed
Market Cap: 8.7B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+42%
Revenue
Forecast
+19%
Operating Income
Forecast
+125%
Net Income
Forecast
+97%

Wall Street
Price Targets

Price Targets Summary
CARsgen Therapeutics Holdings Ltd

Wall Street analysts forecast CARsgen Therapeutics Holdings Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CARsgen Therapeutics Holdings Ltd is 10.49 HKD with a low forecast of 9.15 HKD and a high forecast of 12.08 HKD.

Lowest Forecast
Wall Street Target
9.15 HKD
40% Downside
Average Forecast
Wall Street Target
10.49 HKD
31% Downside
Highest Forecast
Wall Street Target
12.08 HKD
20% Downside
Lowest
Price Target
9.15 HKD
40% Downside
Average
Price Target
10.49 HKD
31% Downside
Highest
Price Target
12.08 HKD
20% Downside
CARsgen Therapeutics Holdings Ltd Competitors:
Price Targets
P
PRME
Prime Medicine Inc
679% Upside
1530
3SBio Inc
7% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
67% Upside
GYRE
Gyre Therapeutics Inc
188% Upside
P
PRME
Prime Medicine Inc
679% Upside
1530
3SBio Inc
7% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
67% Upside
GYRE
Gyre Therapeutics Inc
188% Upside
ALERS
Eurobio Scientific SA
22% Upside
MNKD
MannKind Corp
103% Upside
ELDN
Eledon Pharmaceuticals Inc
220% Upside
OXB
Oxford BioMedica PLC
86% Upside

Revenue
Forecast

Revenue Estimate
CARsgen Therapeutics Holdings Ltd

The compound annual growth rate of CARsgen Therapeutics Holdings Ltd's revenue for the next 2 years is 603%.

N/A
Past Growth
603%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
CARsgen Therapeutics Holdings Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
CARsgen Therapeutics Holdings Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
12%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CARsgen Therapeutics Holdings Ltd's stock price target?
Price Target
10.49 HKD

According to Wall Street analysts, the average 1-year price target for CARsgen Therapeutics Holdings Ltd is 10.49 HKD with a low forecast of 9.15 HKD and a high forecast of 12.08 HKD.

What is CARsgen Therapeutics Holdings Ltd's Revenue forecast?
Projected CAGR
603%

The compound annual growth rate of CARsgen Therapeutics Holdings Ltd's revenue for the next 2 years is 603%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 243,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.